The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence - 30/07/22
Doi : 10.1016/j.jinf.2022.06.004
Ling Sang a, c, e, 1, Bo Cheng b, c, 1, Yuheng Yu a, c, e, 1, Yin Xi a, c, e, 1, Yun Wang e, Bingdong Fan e, Jijie Li f, Jingtao Dai g, Guifen Gan h, Shijun Tong h, Bin Sun i, Xiaojing Qi j, Wenhua Liang b, c, ⁎ 
, Jianxing He b, c, ⁎ , Nanshan Zhong c, d
, Jianxing He b, c, ⁎ , Nanshan Zhong c, d a Department of Intensive Care Unit, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
b Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou 510120, China
c Guangzhou Laboratory, Guangzhou International Biotech Island, Guangzhou 510320, China
d Department of Respiratory Medicine, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou 510120, China
e Department of Emergency Intensive Care Unit (EICU), Qinghai Provincial Fourth People's Hospital, China
f Department of Respiratory Medicine, Qinghai Provincial Fourth People's Hospital, China
g Department of Respiratory Intensive Care Medicine, The Qinghai Provincial Fourth People's Hospital, China
h Department of Critical Care Medicine, The Affiliated Hospital of Qinghai University, China
i Department of Critical Care Medicine, Qinghai Provincial People's Hospital, China
j Department of Respiratory and Critical Care Medicine, Qinghai Provincial People's Hospital, China
⁎Corresponding authors at: Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou 510120, China.Department of Thoracic Surgery and OncologyState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory DiseaseThe First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou Institute of Respiratory HealthGuangzhou510120China
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | IBI314 has a satisfying potency in Delta and Omicron-infected patients. |
• | IBI314 is generally well-tolerated, with no serious adverse events observed. |
• | IBI314 is effective in any stage of COVID-19 cases. |
• | The earlier use of IBI314 might lead to better efficacy. |
Plan
© 2022
Publié par Elsevier Masson SAS.
Vol 85 - N° 3
P. 334-363 - septembre 2022 Retour au numéro
Article précédent
- Single-cell RNA sequencing analysis of liver reveals the enhanced entry and release abilities of human adenovirus F41, partially explaining acute hepatitis in children
- Junwen Luan, Yixuan Zhou, Xiao Wang, Annan Ming, Yuwen Liu, Yupei Yuan, Junhan Liang, Leiliang Zhang
- Evaluating the potential impact of COVID-19 passports in Lithuania
- Mindaugas Stankūnas, Algis Džiugys, Gediminas Skarbalius, Edgaras Misiulis, Robertas Navakas
Bienvenue sur EM-consulte, la référence des professionnels de santé.